Rand兰德：一直到2020年-国防部认可的19疫苗授权的成本效益分析报告（英文版）

the Department of Defense (DoD) faced challenges during the COVID-19 pandemic, including the implementation of vaccine policies to maintain operational readiness and troop health. This retrospective, ex ante analysis examines the cost-benefit implications of the COVID-19 vaccine mandate implemented by the DoD in August 2021, following the full FDA licensing of the Pfizer-BioNTech Comirnaty vaccine. The mandate aimed to enhance force health protection against the virus, yet resulted in signifi